Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

63Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.

Cite

CITATION STYLE

APA

van der Geest, K. S. M., Sandovici, M., van Sleen, Y., Sanders, J. S., Bos, N. A., Abdulahad, W. H., … Brouwer, E. (2018, September 1). Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? Arthritis and Rheumatology. John Wiley and Sons Inc. https://doi.org/10.1002/art.40520

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free